xmpritolimod (CNT101) / Connext - LARVOL DELTA

Orphan Designation: prevention of acute graft-versus-host disease (aGvHD) (FDA) - Date Designated: 08/23/2024

Orphan drug • Acute Graft versus Host Disease • Graft versus Host Disease

Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model. (PubMed, Int J Med Sci) - "Finally, macrophages harvested from the spleens of mice treated with KMRC011-primed MSCs showed a significant increase in the anti-inflammatory M2 phenotype. Overall, the results suggest that KMRC011-primed MSCs attenuated GVHD severity in mice by polarizing macrophages to the M2 phenotype and increasing the proportion of anti-inflammatory cells, opening new horizons for GVHD treatment."

IO biomarker • Journal • Preclinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Inflammation • Transplantation • CSF1 • IL10

Looking for the phoenix: the current research on radiation countermeasures. (PubMed, Int J Radiat Biol) - "10 of these studies had been completed, 3 with promising KMRC011 increased G-CSF, IL-6, and neutrophil counts suggesting potential for the treatment of hematopoietic acute radiation syndrome (H-ARS); GC4419 reduced the number of patients with severe oral mucositis and its duration; the combination of enoxaparin, pentoxifylline, and ursodeoxycholic acid reduced the incidence of focal radiation-induced liver injury. To overcome this problem, there is a need to involve more public resources in funding. Among the technological opportunities, a deeper use of in silico approaches seems to be prospective."

Journal • Hepatology • Liver Failure • Mucositis • Oncology • Stomatitis • CSF3 • IL6

Connext, Acute Graft-versus-Host Disease Drug Approval for Domestic Clinical Phase 1 IND [Google translation] (Money Today) - "Connext announced on the 25th that it had recently obtained approval from the Ministry of Food and Drug Safety for its clinical trial protocol (IND) submitted for the phase 1 clinical trial of 'CNT101', a candidate for treatment of acute graft-versus-host disease."

IND • Acute Graft versus Host Disease • Graft versus Host Disease